Recently, transplantation of constructed tissue sheets from human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) has proven to be effective in treating ischemic cardiomyopathy, with the first clinical trial in progress. Poly(lactic-co-glycolic acid) (PLGA) is a biocompatible and biodegradable copolymer, widely used in drug delivery and tissue engineering. In our previous study, we constructed a hiPSC-CM tissue with a three-dimensional and parallel composition based on aligned PLGA fibers used for treating myocardial infarction (MI). Its therapeutic effects on the recovery of cardiac function have been confirmed in rat and porcine MI models. Increasing the initial number of transplanted cells can further improve cardiac functional recovery. 

However, the challenge of ensuring the survival or retention of transplanted cells persists. Oxygen diffusion limitations, lack of trophic factors, and hypoxia-related issues, are common complications in cell transplants. To increase graft survival, the administration of vascular endothelial growth factor (VEGF) or increasing VEGF or related gene expression in engrafted cells, has proven to be an effective method. However, in vivo half-life of VEGF is short (∼30 min), which precludes long-term administration to the infarcted heart with just a single operation. Therefore, compounds that promote endogenous VEGF secretion would provide a feasible solution to this limitation.

visit for more articles at Journal of Heart and Cardiovascular Research

Kindly submit your article at  https://www.imedpub.com/submissions/heart-cardiovascular-research.html

Regards
Mishita
Jornal co-ordinator
Journal of Heart and Cardiovascular Research